Inovio cancer drug hits primary endpoint in Phase 2 trial

In a Phase 2 clinical trial evaluating Inovio Pharmaceuticals' VGX-3100 as a treatment for biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3), the cancer immunotherapy candidate achieved its primary endpoint of histopathological regression of CIN2/3 to CIN1 or no disease. It also demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected compared to placebo.

The company plans to present top-line results at the 2014 International Society of DNA Vaccines Conference in San Diego on July 23, 2014.

(INO +14.3%) are up on robust volume in early trading.

From other sites
Comments (15)
  • bengman007
    , contributor
    Comments (8) | Send Message
    Congrats to DR KIM!
    23 Jul 2014, 09:48 AM Reply Like
  • SCLP
    , contributor
    Comments (113) | Send Message
    Roche in 2006 pulled out of a HPV vaccine that showed the same results
    nothing new here, its a failure ... looks like somebody is going to raise cash again ... Transgene .. was the company if you want to research it, they are still trying to make it work .. Best in Class ... ? dont think so ... against cancer this platform has no chance is these results are anything to go by ..
    27 Jul 2014, 09:04 AM Reply Like
  • Biologist/investor
    , contributor
    Comments (33) | Send Message
    hot d@mn! More info please!
    23 Jul 2014, 09:52 AM Reply Like
  • dhdhoora
    , contributor
    Comments (796) | Send Message
    These results really validate Inovio's approach and should apply across a broad spectrum of pre-cancers, cancers, and chronic infections -- according to the good Dr. Kim! Yea!
    23 Jul 2014, 09:59 AM Reply Like
  • TPF1115
    , contributor
    Comments (12) | Send Message
    I stuck with this stock through hard times, just recently the shorts kept knocking this stock down. Now we are starting to see the great value here. This is just the beginning, with the stock up 24% +. There is much more in the pipeline, we will see much more upside in the coming months, and years to come.
    23 Jul 2014, 10:08 AM Reply Like
  • jeepman58
    , contributor
    Comments (225) | Send Message
    Congratulations to Dr. Kim and his outstanding team!!! He's put together a special group of researchers and partners. What a tremendous step forward in the fight against - and cure for - some cancers. Absolutely life-changing for many women.

    23 Jul 2014, 10:21 AM Reply Like
  • ronster3
    , contributor
    Comments (19) | Send Message
    With good news why does Adam F continue to trash this company ?
    23 Jul 2014, 11:07 AM Reply Like
  • ChuckGlenn
    , contributor
    Comments (18) | Send Message
    Simple. he shorted it. It's pretty obvious he has more than a passive interest in Inovio.
    23 Jul 2014, 11:22 AM Reply Like
  • Cassandra.says
    , contributor
    Comments (91) | Send Message
    Ding dong, the witch is dead!


    The utterly unqualified Adam Feuerstein will never live this one down, and a very good thing that is.


    Adam has an undergraduate degree in political science (NOT a science) and gives his credentials for writing about biotech as his years of having done so for Jim Cramer. Not much to crow about. Cramer is notorious for self-promotion by shouting, going red in the face and jumping up and down on the sacred idiot box. Cramer was bullish on the banking sector, and scornful of all warnings, just before the bust. Obviously, Adam was hired as an attention-getting device.


    Everybody knows small cap biotech is high risk, high reward. If you knock everything that emerges from the sector, you are merely playing the odds and don't have to understand the processes you are opining about to be right some of the time. The value play is to find an analyst like Jason Napodano, with both education and work experience in both biotech and finance, who works his ass off to evaluate the science underlying the program and pipeline of the small biotechs and shares it, without underplaying the risks for small bio when financing has virtually dried up.
    23 Jul 2014, 11:51 AM Reply Like
    , contributor
    Comment (1) | Send Message
    with love from belgium regards
    23 Jul 2014, 12:46 PM Reply Like
  • Capt. McNoeffinklu
    , contributor
    Comments (2) | Send Message
 I am long INO so not bashing. There was one concerning statement here to me and I am curious of others thoughts.


    "But Inovio's per-protocol analysis of the study's primary endpoint omits patients. How many patient are missing from the analysis? We don't know because Inovio didn't disclose. The study was designed to enroll 148 patients, according to a design schema on, but Inovio could have enrolled more. If 148 patients were enrolled, Inovio's per protocol analysis omits five patients -- four treated with VGX-3100 and one patient on placebo. "


    Why would data be excluded from analysis? Could be justifiable but to not address it makes me suspicious.
    23 Jul 2014, 01:50 PM Reply Like
  • holydawn
    , contributor
    Comments (146) | Send Message
    Yes, it may be justified since there are a variety of reasons why patients would be excluded due to pregnancy, health issues, etc. It's a straw argument at best.
    23 Jul 2014, 03:18 PM Reply Like
  • holydawn
    , contributor
    Comments (146) | Send Message
    "Why would data be excluded from analysis? Could be justifiable but to not address it makes me suspicious."


    straw man argument to be precise
    23 Jul 2014, 03:19 PM Reply Like
  • larrie
    , contributor
    Comments (40) | Send Message
    This is great news for patients! Congrats to Dr Kim and his staff!
    23 Jul 2014, 03:20 PM Reply Like
  • Roger Tracy
    , contributor
    Comments (5) | Send Message
    Wonderful, just simply wonderful. I have had INO as far back as 2009 and I can tell you my wife is a RN OCN. She got my interest up in this company, and it has been well deserved. Thanks to INO and my wife. Go INO
    23 Jul 2014, 03:43 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs